Urology Times asked Maha H. Hussain, MD: How will the advent of PARP inhibitors change the management of advanced prostate cancer?
Urology Times asked Maha H. Hussain, MD: How will the advent of PARP inhibitors change the management of advanced prostate cancer?
For more on PARP inhibitors, see: PARP inhibitor significantly extends rPFS vs. hormonal therapy
More videos:
Focal therapy vs. surveillance for low-risk PCa
Medicare final rule: Changes affect cysto, prostate Bx reimbursement
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.